Investigation launched into ADMA Biologics for possible revenue inflation via channel-stuffing.

Berger Montague PC is investigating ADMA Biologics' Board for potential breaches of fiduciary duty related to alleged channel-stuffing to boost revenue despite falling demand for its main product, ASCENIV. This legal probe could impact shareholder confidence and the company's reputation. Investors interested in the case can contact Berger Montague for more information. ADMA is a biopharmaceutical firm specializing in immune deficiency treatments, headquartered in New Jersey.

Following the news of Berger Montague PC's investigation into ADMA Biologics' board, the company's shares are trading at USD 9.35 on Pluang as of Sep 14, 2026 20:32 WIB. The stock has seen a modest 1.30% increase in the last day. ADMA's market capitalization stands at $2.07 billion, with a 52-week trading range between $7.60 and $20.38, indicating significant volatility over the past year.